Optional Non-CME Satellite Presentations

Discussion of Brukinsa for Adult Patients with CLL/SLL

Moshe Levy, MD
Director, Hematologic Malignancies
Baylor University Medical Center
Dallas, TX

Location: Hemisphere Dancer Room, 9th Floor

RSVP: Darwin Torres-Portalatin
(954) 732-9933
[email protected]

This program is developed and offered by BeiGene, Ltd.

The first and only FDA-approved anti-CD38 + VRd therapy in patients with NDMM not eligible for transplant

Raymond Thertulien, MD, PhD
Director, Myeloma & Plasma Cell Disorders
Novant Health, Weisiger Cancer Institute

Location: Hemisphere Dancer Room, 9th Floor

This program is developed and offered by Sanofi.

Elevate the Possibilities: TRODELVY in Pretreated HR+/HER2- mBC and mTNBC

Monica Fornier, MD
Associate Member, Breast Medicine Service
Memorial Sloan Kettering Cancer Center
New York, New York

Location: Hemisphere Dancer Room, 9th Floor

This program is developed and offered by Gilead.

Breakthrough Innovation: The First and Only Bispecific T-cell Engager (BiTE®) Therapy for 2L+ Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Tarek Mekhail, MD

Location: Hemisphere Dancer Room, 9th Floor

RSVP: Kaylie Bond
[email protected]
908-892-9985

This program is developed and offered by Amgen.